The Hematologist

In this episode, Contributing Editor Ajai Chari, MD, a professor of clinical medicine and director of the myeloma program at the University of California San Francisco, talks with Pieter Sonneveld, MD, PhD, a professor of hematology at the Erasmus University of Rotterdam in the Netherlands. They discuss Dr. Sonneveld’s recent paper, “Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma,” published in The New England Journal of Medicine. Dr. Chari wrote about Dr. Sonneveld’s paper in The Hematologist with his Diffusion article, “Four Is Better Than Three: Will We Finally Agree?” 

Disclosures: Dr. Chari has received consulting fees from Abbvie, Adaptive, Amgen, Antengene, Bristol Myers Squibb, Forus, Genentech/Roche, Glaxo Smith Klein, Janssen, Karyopharm, Millenium/Takeda, and Sanofi/Genzyme and received research funding from Janssen. Dr. Sonneveld has served on the advisory board of Pfizer and has received research funding and served on the advisory boards of Amgen, Bristol Myers Squibb, Celgene, Janssen, and Karyopharm.

Music: “Jellyfish in Space” Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/